Background: We recognize an unprecedented opportunity to study the effects of withdrawing one or more chronic treatments in people with CF (PwCF) who benefit greatly from CFTR modulator therapy, but feasibility and acceptance of such a study within the community is unknown.
Methods: We surveyed PwCF, their families, and their acquaintances between November 16, 2018, and December 2, 2018, and CF clinicians between December 19, 2018, and January 2, 2019, about treatment withdrawal research. We sought feedback from these groups about their level of interest in this research, the consistency with which they were taking modulator and non-modulator treatments, the ways in which they conceptualized health changes, and what chronic non-modulator treatments they were most interested in stopping. We also asked for stakeholder perspectives on the design of a treatment withdrawal trial, but we intend to report these perspectives elsewhere.
Results: Eighty percent (541/675) of CF community respondents and 95% (206/218) of CF clinicians said that a trial of treatment simplification should be performed in the context of highly effective modulator therapy. Most current CFTR modulator users (292/359, 81%) have not stopped another chronic treatment. Worsening lung function by spirometry or increased daily symptoms were important health indicators. PwCF, their families, and/or their acquaintances ranked airway clearance techniques and inhaled antibiotics as the most burdensome treatments.
Conclusions: There is considerable support among the CF community and CF clinicians in the U.S. for controlled trials to assess the safety and impact of treatment simplification in patients taking highly effective modulator therapy.
Keywords: Cystic fibrosis; Modulator; Survey; Treatment burden; Withdrawal study.
Copyright © 2019. Published by Elsevier B.V.
The Impact of CFTR Modulator Therapies on CF Airway MicrobiologyGB Rogers et al. J Cyst Fibros. PMID 31416774. - ReviewMajor historical advances in cystic fibrosis (CF) respiratory clinical care, including mechanical airway clearance and inhaled medications, have aimed to address the cons …
Correctors (Specific Therapies for Class II CFTR Mutations) for Cystic FibrosisKW Southern et al. Cochrane Database Syst Rev 8 (8), CD010966. PMID 30070364. - ReviewThere is insufficient evidence that monotherapy with correctors has clinically important effects in people with CF who have two copies of the F508del mutation.Combination …
Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Precision Medicine in Cystic FibrosisEB Burgener et al. Curr Opin Pediatr 30 (3), 372-377. PMID 29538046. - ReviewCFTR modulator therapy targets the protein defective in CF and boosts its function, but the drug must match mutation pathobiology. Ivacaftor, a CFTR potentiator, was the …
Topical Cystic Fibrosis Transmembrane Conductance Regulator Gene Replacement for Cystic Fibrosis-Related Lung DiseaseTW Lee et al. Cochrane Database Syst Rev (6), CD005599. PMID 27314455. - ReviewOne study of liposome-based CFTR gene transfer therapy demonstrated some improvements in respiratory function in people with CF, but this limited evidence of efficacy doe …
Can Exercise Replace Airway Clearance Techniques in Cystic Fibrosis? A Survey of Patients and Healthcare ProfessionalsNJ Rowbotham et al. J Cyst Fibros. PMID 31740105.Airway clearance techniques (ACTs) are recommended in cystic fibrosis (CF) to prevent accumulation of secretions and lung infection. "Can exercise replace chest physiothe …